Lördag 21 December | 15:36:39 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-02-27 12:00 Kvartalsrapport 2025-Q2
2024-12-09 - X-dag ordinarie utdelning ODI 0.00 SEK
2024-11-22 - Kvartalsrapport 2025-Q1
2024-11-19 - Extra Bolagsstämma 2024
2024-08-29 - Bokslutskommuniké 2024
2024-05-30 - Kvartalsrapport 2024-Q3
2024-02-22 - Kvartalsrapport 2024-Q2
2023-12-18 - X-dag ordinarie utdelning ODI 0.00 SEK
2023-12-15 - Årsstämma
2023-11-23 - Kvartalsrapport 2024-Q1
2023-08-24 - Bokslutskommuniké 2023
2023-05-25 - Kvartalsrapport 2023-Q3
2023-02-23 - Kvartalsrapport 2023-Q2
2022-12-16 - Årsstämma
2022-12-02 - X-dag ordinarie utdelning ODI 0.00 SEK
2022-11-24 - Kvartalsrapport 2023-Q1
2022-08-25 - Bokslutskommuniké 2022
2022-05-25 - Kvartalsrapport 2022-Q3
2022-02-24 - Kvartalsrapport 2022-Q2
2021-12-14 - X-dag ordinarie utdelning ODI 0.00 SEK
2021-12-13 - Årsstämma
2021-11-25 - Kvartalsrapport 2022-Q1
2021-08-26 - Bokslutskommuniké 2021
2021-05-27 - Kvartalsrapport 2021-Q3
2021-02-25 - Kvartalsrapport 2021-Q2
2020-12-28 - X-dag ordinarie utdelning ODI 0.00 SEK
2020-12-14 - Årsstämma
2020-11-27 - Kvartalsrapport 2021-Q1
2020-08-27 - Bokslutskommuniké 2020

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriLäkemedel & Handel
ODI Pharma är en producent samt leverantör av medicinska cannabisprodukter. Verksamheten drivs via dotterbolag och partners där försäljningen går via grossistdistributörer samt apotek. Produkterna används för behandling av exempelvis multipel skleros, kronisk smärta samt vid kemoterapi. Verksamhet återfinns inom den europeiska marknaden, med huvudkontoret i Stockholm.
2020-11-19 12:15:07

The Board of Directors and the Chief Executive Officer of ODI Pharma AB ("ODI") hereby publish the annual report of the fiscal year 2019/2020. The annual report, along with the accompanying auditor's report, is available as an attached file and on the websites of ODI (www.odipharma.com) and Spotlight Stock Market (www.spotlightstockmarket.com). An English translation of the annual report is also available on www.odipharma.com.

For more information on ODI Pharma, please contact:

Derek Simmross, CEO, ODI Pharma AB

E-mail: info@odipharma.com

ODI Pharma AB

ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. ODI will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.